Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category A/B
Category C
Anticoagulant
Anticoagulant